# Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain

> **NCT03564548** · PHASE2 · UNKNOWN · sponsor: **Tetra Bio-Pharma** · enrollment: 20 (estimated)

## Conditions studied

- Cancer
- Breakthrough Cancer Pain

## Interventions

- **DRUG:** PPP001
- **DRUG:** Morphine sulfate or Hydromorphone or Oxycodone

## Key facts

- **NCT ID:** NCT03564548
- **Lead sponsor:** Tetra Bio-Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-26
- **Primary completion:** 2022-03
- **Final completion:** 2022-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03564548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03564548, "Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03564548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*